{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:36Z","timestamp":1787020236402,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["IRG-08-060-04"],"award-info":[{"award-number":["IRG-08-060-04"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["IRG-08-060-04"],"award-info":[{"award-number":["IRG-08-060-04"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic cancer (PC) is one of the most aggressive and challenging cancer types to effectively treat, ranking as the fourth-leading cause of cancer death in the United States. We investigated if exposures to angiotensin II receptor blockers (ARBs) or angiotensin I converting enzyme (ACE) inhibitors after PC diagnosis are associated with survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PC patients were identified by ICD-9 diagnosis and procedure codes among the 3.7 million adults living in the Emilia-Romagna Region from their administrative health care database containing patient data on demographics, hospital discharges, all-cause mortality, and outpatient pharmacy prescriptions. Cox modeling estimated covariate-adjusted mortality hazard ratios for time-dependent ARB and ACE inhibitor exposures after PC diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>8,158 incident PC patients were identified between 2003 and 2011, among whom 20% had pancreas resection surgery, 36% were diagnosed with metastatic disease, and 7,027 (86%) died by December 2012. Compared to otherwise similar patients, those exposed to ARBs after PC diagnosis experienced 20% lower mortality risk (HR=0.80; 95% CI: 0.72, 0.89). Those exposed to ACE inhibitors during the first three years of survival after PC diagnosis experienced 13% lower mortality risk (HR=0.87; 95% CI: 0.80, 0.94) which attenuated after surviving three years (HR=1.14; 95% CI: 0.90, 1.45).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of this large population study suggest that exposures to ARBs and ACE inhibitors after PC diagnosis are significantly associated with improved survival. ARBs and ACE inhibitors could be important considerations for treating PC patients, particularly those with the worst prognosis and most limited treatment options. Considering that these common FDA approved drugs are inexpensive to payers and present minimal increased risk of adverse events to patients, there is an urgent need for randomized clinical trials, large simple randomized trials, or pragmatic clinical trials to formally and broadly evaluate the effects of ARBs and ACE inhibitors on survival in PC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-022-09200-4","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T01:02:33Z","timestamp":1644195753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Angiotensin blockade therapy and survival in pancreatic cancer: a population study"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9428-1151","authenticated-orcid":false,"given":"Scott W.","family":"Keith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9971-6989","authenticated-orcid":false,"given":"Vittorio","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwyda A.","family":"Arafat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5604-721X","authenticated-orcid":false,"given":"Matthew","family":"Alcusky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Rabinowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Lavu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Z.","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"key":"9200_CR1","volume-title":"Cancer Facts & Figures 2021","author":"American Cancer Society","year":"2021","unstructured":"American Cancer Society. Cancer Facts & Figures 2021. Atlanta: American Cancer Society; 2021."},{"issue":"5","key":"9200_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12032-017-0951-0","volume":"34","author":"F D\u2019Angelo","year":"2017","unstructured":"D\u2019Angelo F, Antolino L, Farcomeni A, et al. Neoadjuvant treatment in pancreatic cancer: Evidence-based medicine? A systematic review and meta-analysis. Med Oncol. 2017;34(5):85.","journal-title":"Med Oncol."},{"issue":"4","key":"9200_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/1756283X13478680","volume":"6","author":"PE Oberstein","year":"2013","unstructured":"Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6(4):321\u201337.","journal-title":"Therap Adv Gastroenterol."},{"issue":"9","key":"9200_CR4","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/carcin\/bgn171","volume":"29","author":"EI Ager","year":"2008","unstructured":"Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis. 2008;29(9):1675\u201384.","journal-title":"Carcinogenesis."},{"key":"9200_CR5","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1038\/ncomms3516","volume":"4","author":"VP Chauhan","year":"2013","unstructured":"Chauhan VP, Martin JD, Liu H, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516.","journal-title":"Nat Commun."},{"issue":"5","key":"9200_CR6","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jamcollsurg.2007.01.067","volume":"204","author":"HA Arafat","year":"2007","unstructured":"Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surgeons. 2007;204(5):996\u20131005.","journal-title":"J Am Coll Surgeons."},{"issue":"1","key":"9200_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11605-007-0403-9","volume":"12","author":"R Anandanadesan","year":"2008","unstructured":"Anandanadesan R, Gong Q, Chipitsyna G, Witkiewicz A, Yeo CJ, Arafat HA. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1\/2 signaling. J Gastrointestinal Surg. 2008;12(1):57\u201366.","journal-title":"J Gastrointestinal Surg"},{"issue":"9123","key":"9200_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","volume":"352","author":"AF Lever","year":"1998","unstructured":"Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352(9123):179\u201384.","journal-title":"Lancet."},{"issue":"9","key":"9200_CR9","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L","volume":"92","author":"S Friis","year":"2001","unstructured":"Friis S, Sorensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer. 2001;92(9):2462\u201370.","journal-title":"Cancer."},{"issue":"9281","key":"9200_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0140-6736(01)05704-X","volume":"358","author":"LH Lindholm","year":"2001","unstructured":"Lindholm LH, Anderson H, Ekbom T, et al. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet. 2001;358(9281):539\u201344.","journal-title":"Lancet."},{"issue":"6","key":"9200_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000337979","volume":"83","author":"ST Kim","year":"2012","unstructured":"Kim ST, Park KH, Oh SC, et al. How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? Oncology. 2012;83(6):354\u201360.","journal-title":"Oncology."},{"issue":"10","key":"9200_CR12","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00432-009-0587-3","volume":"135","author":"S Wilop","year":"2009","unstructured":"Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009;135(10):1429\u201335.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"9200_CR13","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/sj.bjc.6605955","volume":"103","author":"Y Nakai","year":"2010","unstructured":"Nakai Y, Isayama H, Ijichi H, et al. Inhibition of renin\u2013angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Brit J Cancer. 2010;103(11):1644\u20138.","journal-title":"Brit J Cancer."},{"issue":"9","key":"9200_CR14","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1007\/s00268-017-4021-8","volume":"41","author":"M Cerullo","year":"2017","unstructured":"Cerullo M, Gani F, Chen SY, Canner JK, Pawlik TM. Impact of Angiotensin Receptor Blocker Use on Overall Survival Among Patients Undergoing Resection for Pancreatic Cancer. World J Surg. 2017;41(9):2361\u201370.","journal-title":"World J Surg."},{"issue":"7","key":"9200_CR15","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","volume":"5","author":"JE Murphy","year":"2019","unstructured":"Murphy JE, Wo JY, Ryan DP, et al. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019;5(7):1020\u20137.","journal-title":"JAMA Oncol."},{"key":"9200_CR16","unstructured":"ClinicalTrials.gov. Losartan and nivolumab in combination with FOLFIRINOX and SBRT in localized pancreatic cancer (NCT03563248). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03563248 Accessed 12\/4\/2021."},{"key":"9200_CR17","unstructured":"The Emilia-Romagna Regional Health Service and the new welfare system: Facilities, expenditure, and activities as of 31.12.2010. Programs, agreements and organisational models. Bologna, Italy: Regione Emilia-Romagna Assessorato Politiche per la Salute; 2012."},{"issue":"1","key":"9200_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jcpt.12099","volume":"39","author":"S Sikirica","year":"2014","unstructured":"Sikirica S, Marino M, Gagne JJ, De Palma R, Maio V. Risk of death associated with the use of conventional vs. atypical antipsychotic medications: evaluating the use of the Emilia-Romagna Region database for pharmacoepidemiological studies. J Clin Pharm Ther. 2014;39(1):38\u201344.","journal-title":"J Clin Pharm Ther."},{"issue":"4","key":"9200_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10552-013-0160-x","volume":"24","author":"Z Clancy","year":"2013","unstructured":"Clancy Z, Keith SW, Rabinowitz C, Ceccarelli M, Gagne JJ, Maio V. Statins and colorectal cancer risk: a longitudinal study. Cancer Causes Control. 2013;24(4):777\u201382.","journal-title":"Cancer Causes Control."},{"issue":"4","key":"9200_CR20","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/jcpt.12820","volume":"44","author":"M Alcusky","year":"2019","unstructured":"Alcusky M, Keith SW, Karagiannis T, Rabinowitz C, Louis DZ, Maio V. Metformin exposure and survival in head and neck cancer: A large population-based cohort study. J Clin Pharm Ther. 2019;44(4):588\u201394.","journal-title":"J Clin Pharm Ther."},{"issue":"4","key":"9200_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492\u20139.","journal-title":"Am J Epidemiol."},{"issue":"1","key":"9200_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327.","journal-title":"Med Care."},{"key":"9200_CR23","doi-asserted-by":"crossref","unstructured":"Liu H, Naxerova K, Pinter M, et al. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017.","DOI":"10.1158\/1078-0432.CCR-17-0256"},{"issue":"5","key":"9200_CR24","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00432-014-1873-2","volume":"141","author":"Y Nakai","year":"2015","unstructured":"Nakai Y, Isayama H, Sasaki T, et al. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. J Cancer Res Clin Oncol. 2015;141(5):933\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"9200_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tem.2005.07.009","volume":"16","author":"F Deshayes","year":"2005","unstructured":"Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metabol. 2005;16(7):293\u20139.","journal-title":"Trends Endocrinol Metabol"},{"issue":"1-3","key":"9200_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0167-0115(03)00192-7","volume":"116","author":"PS Leung","year":"2003","unstructured":"Leung PS, Suen PM, Ip SP, Yip CK, Chen G, Lai PB. Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response. Regulatory Peptides. 2003;116(1\u20133):61\u20139.","journal-title":"Regulatory Peptides."},{"issue":"6","key":"9200_CR27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/01.LAB.0000017372.76297.EB","volume":"82","author":"R Tamarat","year":"2002","unstructured":"Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Laboratory Investigation. 2002;82(6):747\u201356.","journal-title":"Laboratory Investigation"},{"issue":"2","key":"9200_CR28","first-page":"355","volume":"22","author":"R Noguchi","year":"2009","unstructured":"Noguchi R, Yoshiji H, Ikenaka Y, et al. Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncol Reports. 2009;22(2):355\u201360.","journal-title":"Oncol Reports."},{"issue":"6","key":"9200_CR29","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/MPA.0000000000000125","volume":"43","author":"S Kim","year":"2014","unstructured":"Kim S, Toyokawa H, Yamao J, et al. Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. Pancreas. 2014;43(6):886\u201390.","journal-title":"Pancreas."},{"issue":"5","key":"9200_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/MPA.0b013e3181c314cd","volume":"39","author":"Q Gong","year":"2010","unstructured":"Gong Q, Davis M, Chipitsyna G, Yeo CJ, Arafat HA. Blocking angiotensin II type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas. 2010;39(5):581.","journal-title":"Pancreas."},{"issue":"5","key":"9200_CR31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.tranon.2016.07.004","volume":"9","author":"V Kumar","year":"2016","unstructured":"Kumar V, Boucher Y, Liu H, et al. Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma. Transl Oncol. 2016;9(5):431\u20137.","journal-title":"Transl Oncol."},{"issue":"7","key":"9200_CR32","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1073\/pnas.1018892108","volume":"108","author":"B Diop-Frimpong","year":"2011","unstructured":"Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad of Sci U S A. 2011;108(7):2909\u201314.","journal-title":"Proc Natl Acad of Sci U S A"},{"issue":"5","key":"9200_CR33","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3109\/00365521.2013.777776","volume":"48","author":"A Masamune","year":"2013","unstructured":"Masamune A, Hamada S, Kikuta K, et al. The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Scand J Gastroenterol. 2013;48(5):602\u20139.","journal-title":"Scand J Gastroenterol."},{"key":"9200_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-2407-10-67","volume":"10","author":"C Doi","year":"2010","unstructured":"Doi C, Egashira N, Kawabata A, et al. Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer. 2010;10:67.","journal-title":"BMC Cancer."},{"issue":"2","key":"9200_CR35","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.surg.2011.06.002","volume":"150","author":"A McGhee","year":"2011","unstructured":"McGhee A, Sivarajah M, Gong Q, et al. Angiotensin II type 2 receptor blockade inhibits fatty acid synthase production through activation of AMP-activated protein kinase in pancreatic cancer cells. Surgery. 2011;150(2):284\u201398.","journal-title":"Surgery."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09200-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T01:03:00Z","timestamp":1644195780000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09200-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9200"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09200-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"24 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted under the auspices of regulation of privacy of the Emilia-Romagna Region N.3 of 24 April 2006 (title: Processing of sensitive data) of act N.1 of 30 May 2014 still in force. This study received expedited review and was approved by the Thomas Jefferson University Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The Authors declare that there is no conflict of interest. The authors\u2019 work was independent of the funders, and this article accurately represents the study results. Dr.\u2019s Alcusky and Karagiannis were post-doctoral fellows with Thomas Jefferson University during their involvement with the study and are currently employed by AbbVie (Karagiannis) and University of Massachusetts Medical School (Alcusky).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}